Clinically Relevant CHK1 Inhibitors Abrogate Wild-Type and Y537S Mutant ERα Expression and Proliferation in Luminal Primary and Metastatic Breast Cancer Cells

By
Justin.choi
-
0
169
The authors evaluated if kinases could be new targets for the treatment of luminal primary and metastatic breast cancers.
[Journal of Experimental & Clinical Cancer Research]
Full Article